Therapeutic:
Sotrovimab (Xevudy)

Return to company overview

GSK Therapeutic Summary Scorecard
Note: While the therapeutic Sotrovimab was developed with the support of Vir Biotechnology, this scorecard evaluates only GSK's practices. 
**Sotrovimab is no longer FDA-approved to treat Covid-19 in areas with high frequency of the BA.2 Omicron subvariant. 

A: Commitments and AccountabilityScoreC: International cooperationScore
A1 The company publishes a global access plan for its productC1 The company commits to C-TAP or MPP
A2 The company commits to comply with human rights standards in relation to product development and marketing C2 The company commits to not enforcing the exclusive rights of Covid-19 related patents
C3 The company supplies to, or signs agreements with, the vaccines or therapeutics pillar of the ACT Accelerator
C4 The company agrees to license its Covid-19 medical products to other companies
E: Equality, non-discrimination & equityScoreT: TransparencyScore
E1 The company makes the active ingredient available on reasonable ground. [Only for therapeutics]T1 The company publishes its R&D costs.
E2 The company commits to full technology transfer to other manufacturersT2 The company publishes its profit margin.
E3 The company commits to non-profit, ‘fair’, or differential pricingT3 The company publishes the average and/or marginal costs of production.
E4 The company equitably distributes supplies globally. [Only applies to vaccines]T4 The company publishes its production capacity.
E5 The company does not seek protection beyond the minimum criteria in TRIPS, or enforces TRIPS+ measures [where applicable]T5 The company publishes the public subsidies it received during product development and/or testing.
E6 The company agrees to waive exclusive rights in regulatory test data [where applicable].T6 The company publishes the text of licensing agreements.
T7 The company registers its clinical trials in public repositories.

GSK Therapeutic Detailed Evaluation

Explore the results of PAF’s research into GSK’s behaviour. Each section is given an overall score; individual criteria are also scored (see icon following the criteria heading). Click on the ‘+’ sign next to each entry to expand and learn more. 

A: Commitments and Accountability

Overall score:

A1 The company publishes a global access plan for its product
  • GSK signed Gates Foundation ‘Commitments to Expanded Access for Covid-19 Diagnostics, Therapeutics and Vaccines’. States on website that GSK is committed to supporting global supply
  • Score:
A2 The company commits to comply with human rights standards in relation to product development and marketing
  • Position statement on human rights, supports UNGPs and other HR documents 
  • Believe that ‘governments are responsible for defining and enforcing a legal human rights framework’, but they ‘recognise that we have a role to play in upholding human rights and in addressing adverse human rights impacts where we are in a position to influence.’
  • Score:

C: International Cooperation

Overall score:

C1 The company commits to C-TAP or MPP
  • No commitment to a responsible licensing mechanism.
  • Score:
C2 The company commits to not enforcing the exclusive rights of Covid-19 related patents
  • No commitment not to enforce patents.
  • Score:
C3 The company supplies to, or signs agreements with, the vaccines or therapeutics pillar of the ACT Accelerator
  • No
  • Score:
C4 The company agrees to license its Covid-19 medical products to other companies
  • Yes, contract manufacturing deal with Samsung Biologics (South Korea). It is unclear whether this deal goes beyond fill-and-finish.
  • Score:

E: Equality, non-discrimination & equity

Overall score:

E1 The company makes the active ingredient available on reasonable ground
  • No evidence of this
  • Score:
E2 The company commits to full technology transfer to other manufacturers 
  • Contract manufacturing deal with Samsung Biologics. The deal does not seem to include technology transfer.
  • Score:
E3 The company commits to non-profit or ‘fair’ pricing

  • 2100 USD per course in the US. Claims of ‘responsible pricing’ on website; but no evidence of fair or non-profit pricing

  • Score:

E4 The company equitably distributes supplies globally.
[Only applies to vaccines]
E5 The company does not seek protection beyond the minimum criteria in TRIPS, or enforces TRIPS+ measures [where applicable]
  • No evidence of enforcing TRIPS- or not enforcing TRIPS+
  • Score:
E6 The company agrees to waive exclusive rights in regulatory test data [where applicable] 
  • No information.
  • Score:

T: Transparency

Overall score:

T1 The company publishes its R&D costs
  • Publishes overall R&D costs for 2021 but not specific to Sotrovimab
  • Score: 
T2 The company publishes its profit margin

  • GSK: £958m  of sales for Sotrovimab, but does not mention a margin

  • Score:  
T3 The company publishes the average and/or marginal costs of production
  • Does not publish the average and/or marginal costs of producing Sotrovimab.
  • Score:
T4 The company publishes its production capacity
  • 2 million doses in the first half of 2022.
  • Score:
T5 The company publishes the public subsidies it received during product development and/or testing

  • Partially funded by Operation Warp Speed. This is not published on GSK’s website.

  • Score: 
T6 The company publishes the text of licensing agreements
  • No licensing agreement texts are published.
  • Score:
T7 The company registers its clinical trials in public repositories
  • Registers clinical trials plus results in public clinical trial databases
  • Score: